Equities

Adaptive Biotechnologies Corp

Adaptive Biotechnologies Corp

Actions
  • Price (EUR)4.20
  • Today's Change-0.101 / -2.35%
  • Shares traded500.00
  • 1 Year change-13.68%
  • Beta--
Data delayed at least 15 minutes, as of Sep 20 2024 14:39 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of USD
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments346498353
Total Receivables, Net384017
Total Inventory141419
Prepaid expenses119.4413
Other current assets, total------
Total current assets410562403
Property, plant & equipment, net120164173
Goodwill, net119119119
Intangibles, net5.136.838.53
Long term investments--0217
Note receivable - long term------
Other long term assets3.592.060.88
Total assets661857923
LIABILITIES
Accounts payable7.728.083.31
Accrued expenses323730
Notes payable/short-term debt000
Current portion long-term debt/capital leases------
Other current liabilities, total496481
Total current liabilities88110114
Total long term debt1311250
Total debt1311250
Deferred income tax------
Minority interest(0.12)(0.07)0.11
Other liabilities, total134157205
Total liabilities353392319
SHAREHOLDERS EQUITY
Common stock0.010.010.01
Additional paid-in capital1,4531,3871,324
Retained earnings (accumulated deficit)(1144)(919)(719)
Treasury stock - common------
Unrealized gain (loss)------
Other equity, total0.22(4.12)(1.14)
Total equity308464604
Total liabilities & shareholders' equity661857923
Total common shares outstanding145143141
Treasury shares - common primary issue000
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.